Eli Lilly Expands Hims & Hers Partnership with Zepbound, KwikPen and Foundayo Access
Eli Lilly enabled Hims & Hers to prescribe Zepbound vials, KwikPen and Foundayo via LillyDirect with self-pay pricing, expanding its GLP-1 distribution. After Novo Nordisk’s 72% market plunge and with patent protection until 2036, analysts forecast next week’s earnings will show continued growth.
1. Partnership Expansion with Hims & Hers
Hims & Hers now enables licensed clinicians to prescribe Eli Lilly’s weight loss therapies—Zepbound vials, KwikPen pens and the Foundayo tablet—directly through LillyDirect, extending its telehealth platform to support GLP-1 access.
2. Distribution and Pricing Mechanism
Prescriptions issued via the integrated platform use self-pay pricing options that give patients transparent out-of-pocket cost estimates while leveraging LillyDirect’s fulfillment network for efficient therapy delivery.
3. Competitive Landscape and Market Share Shifts
After Novo Nordisk’s share plunged 72% this month following decelerating GLP-1 growth and increased competition, Eli Lilly’s expanded distribution partnerships position it to capture additional market share in the obesity treatment sector.
4. Earnings Outlook and Patent Moat
Analysts anticipate Eli Lilly’s next earnings report will show sustained revenue growth from its GLP-1 portfolio, supported by patent protections on its flagship therapies through 2036 that ensure long-term exclusivity.